15 Best Selling Most Profitable Drugs of All Time

Page 14 of 16

 3. Seretide

Seretide is a treatment for chronic asthma and chronic obstructive pulmonary disease. The drug was launched in 2001 and as of the end of 2016, had generated revenue of $92.52 billion. Pharmaceutical giant GlaxoSmithKline plc (ADR) (NYSE:GSK) lost its patent for Seretide in 2009 for the U.S market and in 2013 for the EU market. Last year, Mylan filed for regulatory approval for the first generic version of Seretide. GlaxoSmithKline has been grilled by investors for not getting the most out of this immensely profitable drug. The company was pushed to file for a new patent after Mylan’s move.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

Page 14 of 16